- Home
- News
- Industry news
- European Commission ∏$approves Roche’s Tecentr£δλiq in combination with Abraxane for p™™eople with PD-L1-positive, metastatic triple-n₩→"≥egative breast cancer
Roche today announced that the European Commi∞±Ωssion has approved Tecentriq® (ate♣γ<☆zolizumab) plus chemothe ÷ε®rapy (Abraxane® [paclitaxel protein-bound par ∑♥ticles for injectable suspensio Ωn (albumin-bound); nab-paclita↑♠xel]) for the treatment of∑↓ < adult patients with unresectable α'locally advanced or metas¶÷tatic triple-negative breast♣& cancer (TNBC) whose tumours have PD-L1 expressi ♠ on (≥1%) and who have not received prior chemot¥ ♦®herapy for metastatic disease. Rocheππ’s VENTANA PD-L1 (SP142♥×) Assay is now CE marked and™≥ commercially availaπ♠♠☆ble in the European Union as an aid f$↕§or identifying patie¥£$§nts with TNBC eligible β♣→for treatment with the Tecentr™α♦iq combination.
“For the past 30 years, we have beenβ©₽ dedicated to transformin®♠₩g the lives of people with bα↑reast cancer. Now, we are pleased to bu ★↔ild on this foundation with ₽the news that the first immunotherapy↓× treatment for triple-negative breast cancer→± is available to people in Europe with PD-±★L1-positive, metastatic triple-ne< gative breast cancer,” sai≥$ £d Sandra Horning, MD, Roche’s Chief MedΩ✔÷'ical Officer and Head of Glob≠÷al Product Development. “The European apλα↔↓proval of this Tecentriq combination λrepresents a significant step forwa ★σrd in the treatment of÷'±α this aggressive breast"♦ cancer, where the unmet medical need is g♠δ≥reat.”
This approval is based on the resu♣ ←lts from the Phase III IMpassio≥∑n130 study. Progression-≥♥φfree survival (PFS) re♣"₩sults demonstrated a stat "ε∏istically significant benefit for Tα♠ ↑ecentriq in combination with¶> nab-paclitaxel and ↔ showed that Tecentriq plus nab-paclitaxel☆≤ significantly reduced the¥ ☆ risk of disease worsening ✘£¥or death (PFS) by 38% compar≈ ed with nab-paclitaxel alone (median PF↑→S=7.5 vs 5 months; hazard ratio [HR]=0≤ .62, 95% CI: 0.49-0.78, p<0.0001) in peop> φle who were tested positive for PD-L1 ex☆↔εpression on tumour-infiltrating immu•≤ne cells. At the second interim analysis, Tδγ♠★ecentriq and nab-paclitaxel showed a clinicall≤"<™y meaningful overall s$•ε<urvival (OS) improvement of s₩✔&even months vs placebo and↕β nab-paclitaxel in the PD-L1-pγ↑↓ositive population (median OS=25.0 vs 18.0 montσ★hs; HR=0.71, 95% CI: 0.54 –0.93). OS £☆>results in the PD-L1-positive popul βation were not formally tested due to ←≈&the hierarchical design of the stud↑®☆↕y as statistical significance was no •∞¶t met for OS in the intention-to-treat (ITT₹ ♣) population (median OS=←♦ε21.0 vs 18.7 months; HR=0.86, 95% CI: 0.72–1.02£¥φ, p=0.078).
The assessment of PD-L1 on tu"γmour-infiltrating immun™♠&e cells is essential for identifying the patie>©nts with TNBC benefi₹✔ting from this Tecentriq combination. PD-L✔≤↓≥1 expression status in th<γε<e IMpassion130 study was assessed by the Vφ←£ENTANA PD-L1 (SP142) assaπ"y.
Safety in the Tecentriq plus ♠♣ nab-paclitaxel arm appear★εγed consistent with the know←©'n safety profiles of the individual medicine≥≥ s, and no new safety signals were identif• ied with the combination. The×γσ nature and incidence σ↕×of severe adverse events (SAEs) aα<nd Grade 3–4 adverse events (A♥<Es) were consistent with the known safety p♥γrofiles of the individual study druδ∏gs or the underlying disease. SAEs were repor☆↕ted in 23% of people receiving Tecentriqλ®•♠ plus nab-paclitaxel compared to 18% of↕☆↓↑ people receiving chemother ≤✔∏apy alone. Grade 3–4 AEs were re÷<ported in 49% of people receiv☆•"ing Tecentriq plus nab-paclitaxel ♥€compared to 42% of people receiving✘& chemotherapy alone.
Currently, there are seven♠< ongoing Phase III studies inve∞"stigating Tecentriq in$>¥δ TNBC, including early and advanced stages of th≤™ ↔e disease.
the 2019 Asia-pacific pharma ✘¶₩βIP Leader Summit will be held in Beijing on November 14-15, and will attract more than 500 industry exp↓↓erts from domestic and foreign ¥÷∞pharmaceutical compan&§≥&ies, biotechnology companies, governm>↔€σents, associations, la♣§w firms, intellectual propφ≠♣₩erty agents and other companies to attend.
Official registration and cons÷®ultation channels:
Contact：Ann
Phone: 021-65650305
From :businessinsuranceU.S. commercial property/cγ✔asualty rates rose 5% on av↔εφerage in the fourth quarter of 2019, up from 4% iε≠¥n the third quarter, reflecting insurers’ i←↔•ntent to continue to increase prices across "♣most lines, online insurance exchange MarketSco∞¶≥ut Corp. said Monday.“Auto rat'π'e increases have been up≤ ±δ all year long; howe★∏☆ver D&O (directors & of©'•ficers) and professional rate increases have s≤ ♦piked significantly in the fourth quarter,” Rich¥σard Kerr, CEO of MarketScout Corp. said §₽in a statement.Insurers ar∏α¥₹e carefully analyzing their •☆§property exposures using c÷<atastrophe modeling tools, he said.ש “We expect many of the major >∞←property catastrophe i≠¶nsurers to curtail their 2020 wri"δtings in California brush and Eas₹<πt and Gulf Coast wind areas. Naturally, th↕✘÷₽is will result in higher rates to insuεσreds,” Mr. Kerr said.D&O liability rates incr•eased by 8.25%, while commeε♠rcial auto increased 8% ♥→¶in the quarter, and professional liability rat♥"es were up 6%, and umbrella/excess rates wereδ↑© up 5.5%, according £α₩÷to MarketScout.Comme♠∞$rcial property rates increased Ω§♠5.25% in the quarter, and business interrupt↔∞ ion rates were up 5%, while all other li™∏λεnes showed smaller increases, excepδ↓<t for workers compensatio$∏π≥n, where rates fell 1%, MarketScout said.By☆≥ industry class, transportation $λ₩and habitational saw the hi™<Ω'ghest average rate inc€✘ ®reases at 9% and 8.25% respectively, M≤ ★arketScout said.Large accoun←∞ts – those with $250,001 to $1 milliδon in premium – saw a rate hik↕₩e of 5.5% in the fourth quarter, as did jumb₹≈↔ o accounts, which have more than $1 milli♠©<♥on in premium. Small accounts – those wi±•→th up to $25,000 in premium – we ≥re up 5%, while mediπβum accounts – those with $25,001 to $250,000 in p©β÷ remium – were up 4.5%₽$ .The “steady trend” of up>÷®¥ward rates reflects ins∑✔∞urers’ plans to continue increasing prices acγ ₽ross all lines exceptπ ∑λ for workers compensation, Marke♦αtScout said.Organizer：Chinσ★•a Insurance Digital &☆±; AI Development 2020Web:http://en.zeγ₽nseegroup.com/p/560573/Contact:Ann 021-6 §₹5650305
From :insurancejournalIt was a relativ®↔₩ely quiet year for the Southeast≠₩®≠ in terms of major catastrophes compared w↕₩δith 2018 when Hurricane’s Michael and F↑ lorence caused major damage i®α€n the region. This year, Hurricaneλ® Dorian sideswiped the Sou₹>theast coast and made landfall on the Oute≤& r Banks of North Caro₽ lina but most of the<≠≠ area was spared. Still, Aon said e™φconomic damage in the U.S. and Canada&n∏↔ bsp;was poised to approach a combin¥δ₩ed $1.5 billion.Flor Ω©ida spent the year recovering from Hurric§✔γ₽ane Michael, which was ε'₽upgraded to a Category 5 storm by NOΩ¶€δAA in April. Florida officials have repeatedly&nb∏λ÷sp;called on the insurance <→★industry to speed up the rec₩✔φαovery process, with nearly 12% of claims still γ∞¶₹open a year after the storm hit.O®π∏rganizer：China Insurance Digital & AI Dα≠∏"evelopment 2020Web:http://eσ$n.zenseegroup.com/p/560573/εΩ™Contact:Ann 021-65650305
From:businessinsuranceλ←→einsurance renewals at Jan. 1, 2020, mainly saw↔↓ single-digit increases, with some exce"★₽ptions, according to reports by reinsuran§≈&±ce brokers released Thursday.Willis Re ε, the reinsurance brokerage₽¥±₹ of Willis Towers Watson ♣₽PLC, and Guy Carpenter &↔δamp; Co. LLC, a unit of Marsh & McLennan Co↑←s. Inc. both reported that year-end reinsuranπ ce renewals varied by ' account and region, but the retrocessiona₽§∞l reinsurance was under pr£essure.Rates on line for property catastrophe rei$ ₩nsurance programs remained stable and property p&∞₩÷er risk pricing was driven by individual p£♥rogram performance, the Willis report said.Alth∏≈<ough some Lloyd’s of London syndicates took f irm positions on rate increases and the ↕σΩLondon market authorized capacity decreased, tha£₩t capactiy was replaced by new capital and a st$₩rong supply from other markets, Williφ'αs Re said.U.S. loss-free accounts renewe♥×"¶d at flat to up 10% while those with l±π¥™osses saw increases of 10% to 50%, the&∏ Willis Re report said, which was among th™§e largest increases. Property catastro©¥phe accounts without losse↔≥s renewed at flat to up 5%, while loss hit ↓γλ×accounts were up 10% to 20%, Willis Reα•↑ said.According to the Guy Carpenter re®σport, the brokerage’s global propertyε↕ catastrophe rate on line in&<∑dex rose 5% in 2019.Acco©≥↓→rding to the Willis Re repo≈©rt, other large incre§←¥ases were seen in Centra∞✔∏l and Eastern Europe, where property p★≈$rograms with losses saw increases o±£f 5% to 20%, and Canada, where εεsuch accounts renewed ✔£'up 10% to 40%.Most other regions and countr☆↑ies saw property increas"•es in the single or low double d±≤Ωigits, the report said.The Jan. 1 renewals sa×♠w some “difficult” negotiations, accord← ing to a letter in the σ↑report from James Kent,✔"& global CEO, Willis Re.The Guy Car¥δλ↓penter report said the reinsurance market was “asε×ymmetrical,” adding “thiΩ&s is certainly not a one-size-fits-all market↑€” and while overall capΩε✔↔acity remained adequate, “allocated capaci♦>ty tightened notably in s$£×♠tressed classes.”Dedicated reinsurance ca'€λpital rose 2% in 2019 and the year saw approxima §'tely $60 billion in σλ∏global insured catastrophe losses, acco∞☆'rding to Guy Carpenter, which was sign÷©ificantly lower than♦∑ 2017 and 2018.Alternative capital, howeγ₽"§ver, contracted by a$≥pproximately 7% percent “←→λas investors were more cautious with ne w investments after assessing mar™ε±ket dynamics and pricing adequa↔>cy,” Guy Carpenter said.The retrocession market “♣was challenged … by t≠"rapped capital, a lack of new capital and ∏₽€continued redemption≠<±↔s from third-party capital provid λφ&ers,” a statement issued with the Gu$>y Carpenter report said.However, significa♥ ♦nt retrocession providers re≥★turned to the market in£ ≥ the past two weeks, Willis Re said.§πγ↕Organizer：China Insurance Digital & AI Dev £elopment 2020Web:http://en.zenseegr<• oup.com/p/560573/Contact:Ann 021-6565030 ♥<<5
Major information technology companies in India ™are running the risk oα ♥f termination of their $1 billion contracts fo$↑¶÷llowing Boeing Co.’s decisiα± on to halt the produc •tion of its 737 Max jets, Mone ≤₹yControl reported citing th÷♦¶☆e Business Standard. Com ±>$panies like Tata Consultancy Services Ltd., Infoσ sys Ltd., HCL Technologies Ltd., Cyient Ltd. a✔∑♠nd L&T Technolog★≈≠y Services Ltd. have outsourcing contra™λα€cts with Boeing or its suβ★$ppliers and Boeing’s jet crisis is$ expected to affect these IT c₩♠ompanies in the short r₽♥un.From:businessinsuranceOrganize€♣r：China Insurance Digital & A≠∑I Development 2020Web:http://en.zeπ×nseegroup.com/p/560573/Contact:Ann 021-65®®≤★650305
France-based eyewear mak↔♦ er Essilor International S.A. ha₽βσs discovered fraudulent activities at one of<≈★∑ its factories in Thailand that could ca♦∞≤<use €190 million ($213 million) in financial l↕↕osses to the company, The Irish Times repor"☆ted citing Reuters. The compaπ↓®"ny has filed complaints in Thailand and hα<≠ as fired all the involved employees. It hoβ pes to recover the losse↑φγ₹s from frozen bank a™×÷$ccounts, insurance and lawsuits.Orga★™↓nizer：China Insurance Digital & AI Develop Ωment 2020Web:http://en.zenseegroup.com/p/56♣♣0573/Contact:Ann 021-65650305
